These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38558544)

  • 1. Severe behavioral and psychological symptoms of dementia successfully treated at home with a blonanserin transdermal patch: A case report.
    Yamaguchi J; Sadahiro R; Hirayama T; Wada S; Nakahara R; Matsuoka H
    Neuropsychopharmacol Rep; 2024 Jun; 44(2):474-478. PubMed ID: 38558544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
    Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
    CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin.
    Hamuro A; Saito S
    Psychogeriatrics; 2010 Dec; 10(4):198-200. PubMed ID: 21159055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study.
    Colombo D; Caltagirone C; Padovani A; Sorbi S; Spalletta G; Simoni L; Ori A; Zagni E
    J Womens Health (Larchmt); 2018 Nov; 27(11):1368-1377. PubMed ID: 30085899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study.
    Ohi K; Takai K; Kuramitsu A; Sugiyama S; Shioiri T
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 113():110470. PubMed ID: 34740708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
    Nishibe H; Tateno A; Sakayori T; Yamamoto M; Kim W; Kakuyama H; Okubo Y
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):108-117. PubMed ID: 32936897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
    Iwata N; Ishigooka J; Kim WH; Yoon BH; Lin SK; Sulaiman AH; Cosca R; Wang L; Suchkov Y; Agarkov A; Watabe K; Matsui T; Sato T; Inoue Y; Higuchi T; Correll CU; Kane JM
    Schizophr Res; 2020 Jan; 215():408-415. PubMed ID: 31471246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D
    Kitamura A; Takagaki T; Nemoto D; Tomita Y; Nishibe H; Kakuyama H
    J Clin Pharmacol; 2021 Aug; 61(8):1069-1080. PubMed ID: 33599975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report.
    Sakai S; Morimoto Y; Matsuzaka Y; Nakano T; Kanegae S; Imamura A; Ozawa H
    Neuropsychopharmacol Rep; 2021 Sep; 41(3):440-443. PubMed ID: 34357702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zotepine for behavioural and psychological symptoms in dementia: an open-label study.
    Rainer MK; Mucke HA; Krüger-Rainer C; Haushofer M; Kasper S
    CNS Drugs; 2004; 18(1):49-55. PubMed ID: 14731059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases.
    Ando K; Suzuki A; Yoshida H
    Respir Investig; 2023 Mar; 61(2):240-246. PubMed ID: 36791594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Behavioral and psychological symptoms in elderly people with cognitive impairment. Differences between assessment at home and at an adult day-care facility].
    Hashidate H; Harada K; Asakawa Y; Yamagami T; Nihei K; Kaneya S; Yoshii C
    Nihon Koshu Eisei Zasshi; 2012 Aug; 59(8):532-43. PubMed ID: 23066632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease.
    Monji A; Takita M; Samejima T; Takaishi T; Hashimoto K; Matsunaga H; Oda M; Sumida Y; Mizoguchi Y; Kato T; Horikawa H; Kanba S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):308-11. PubMed ID: 19138715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch.
    Tomita Y; Takagaki T; Kitamura A; Wada E; Nishibe H; Tateno A; Okubo Y
    J Clin Psychopharmacol; 2022 May-Jun 01; 42(3):260-269. PubMed ID: 35384896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch.
    Hagikura M; Inada T
    Neuropsychopharmacol Rep; 2023 Mar; 43(1):150-153. PubMed ID: 36651841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2016 Sep; 54(2):635-43. PubMed ID: 27497482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Clinical Presentation of Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease According to Sex and Education Level.
    Chang KH; Huang CC; Chen CM; Wu HC; Kuo HC
    J Alzheimers Dis; 2020; 78(2):711-719. PubMed ID: 33044179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community.
    Matsumoto N; Ikeda M; Fukuhara R; Shinagawa S; Ishikawa T; Mori T; Toyota Y; Matsumoto T; Adachi H; Hirono N; Tanabe H
    Dement Geriatr Cogn Disord; 2007; 23(4):219-24. PubMed ID: 17299264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
    Maidment ID; Fox CG; Boustani M; Rodriguez J; Brown RC; Katona CL
    Ann Pharmacother; 2008 Jan; 42(1):32-8. PubMed ID: 18056833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.